Education
About Us
Working with TipRanks
Follow Us
Enovis (ENOV)
NYSE:ENOV
ENOV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$29.13 - $49.83
Previous CloseN/A
Volume391.51K
Average Volume (3M)1.14M
Market Cap
$1.81B
Enterprise Value$3.48B
Total Cash (Recent Filing)$38.46M
Total Debt (Recent Filing)$1.46B
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Jul 31, 2025EPS Estimate
0.72Last Dividend Ex-Date
Apr 05, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)0.81
Shares Outstanding57,123,050
10 Day Avg. Volume1,256,755
30 Day Avg. Volume1,135,262
Financial Highlights & Ratios
PEG Ratio-1.06
Price to Book (P/B)0.78
Price to Sales (P/S)0.00
P/FCF Ratio-52.84
Enterprise Value/Market Cap1.93
Enterprise Value/Revenue0.43
Enterprise Value/Gross Profit3.08
Enterprise Value/Ebitda-3.10
Forecast
1Y Price Target
$57.43Price Target Upside80.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Enovis News
PremiumCompany Announcements
Enovis Holds Annual Meeting, Elects Board Directors
PremiumCompany Announcements
Enovis Corporation’s Strong Q1 2025 Earnings Call
PremiumCompany Announcements
Enovis Corporation Reports Strong Q1 2025 Growth
Bulls Say, Bears Say
Bulls Say
Company StrategyThe setup is especially attractive with Lima integration completed and new products already ramping up.
Financial PerformanceThe company is expected to show organic growth and margin expansion, further enhancing its financial performance.
Product InnovationNew products are ramping up, and some are already contributing to double-digit recon growth.
Bears Say
Guidance AdjustmentManagement raised their revenue guidance but lowered their EBITDA and EPS guidance to account for the impact of tariffs.
Tariff ImpactTariffs are expected to be a $20 million headwind to EBITDA in 2025.
Valuation ConcernsA larger discount to the comp group is imposed despite a higher comp group valuation average.
Ownership Overview
1.75% Insiders
43.87% Mutual Funds
0.57% Other Institutional Investors
27.27% Public Companies and Individual Investors
ENOV FAQ
What was Enovis’s price range in the past 12 months?
Enovis lowest stock price was $29.13 and its highest was $49.83 in the past 12 months.
What is Enovis’s market cap?
Enovis’s market cap is $1.81B.
When is Enovis’s upcoming earnings report date?
Enovis’s upcoming earnings report date is Jul 31, 2025 which is in 52 days.
How were Enovis’s earnings last quarter?
Enovis released its earnings results on May 08, 2025. The company reported $0.81 earnings per share for the quarter, beating the consensus estimate of $0.743 by $0.067.
Is Enovis overvalued?
According to Wall Street analysts Enovis’s price is currently Undervalued.
Does Enovis pay dividends?
Enovis pays a Notavailable dividend of $16.666 which represents an annual dividend yield of N/A. See more information on Enovis dividends here
What is Enovis’s EPS estimate?
Enovis’s EPS estimate is 0.72.
How many shares outstanding does Enovis have?
Enovis has 57,123,050 shares outstanding.
What happened to Enovis’s price movement after its last earnings report?
Enovis reported an EPS of $0.81 in its last earnings report, beating expectations of $0.743. Following the earnings report the stock price went down -3.388%.
Which hedge fund is a major shareholder of Enovis?
Currently, no hedge funds are holding shares in ENOV
Enovis Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$57.43 (80.65% Upside)
$57.43 (80.65% Upside)
Blogger Sentiment
Bullish
ENOV Sentiment 100%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Decreased
By 807.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 7.1%
Last 30 Days ▼ 7.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.61%
12-Months-Change
Fundamentals
Return on Equity
-27.40%
Trailing 12-Months
Asset Growth
-11.02%
Trailing 12-Months
Company Description
Enovis
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.
ENOV Company Deck
ENOV Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong start to the fiscal year 2025 with significant growth in key segments, successful product launches, and improved financial metrics. However, tariff and currency challenges pose potential risks to margins and require strategic mitigation.Read More>ENOV Stock 12 Month Forecast
Average Price Target
$57.43
▲(80.65%Upside)